Stay updated on Oral Azacitidine with Pembrolizumab in Metastatic Melanoma Clinical Trial
Sign up to get notified when there's something new on the Oral Azacitidine with Pembrolizumab in Metastatic Melanoma Clinical Trial page.

Latest updates to the Oral Azacitidine with Pembrolizumab in Metastatic Melanoma Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedRevision: v3.3.2 has been added and Revision: v3.2.0 has been removed, a minor metadata update to the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check20 days agoChange DetectedThe funding-status notice banner was removed. The page previously warned that information may be out of date due to a lapse in government funding.SummaryDifference0.4%

- Check34 days agoChange DetectedOnly minor administrative updates are visible on the page, including the latest update date and minor layout tweaks. The core study details—eligibility criteria, enrollment numbers, study design, and primary/secondary outcomes—appear unchanged.SummaryDifference0.4%

- Check63 days agoChange Detected- Added a government funding lapse notice and current operating status guidance for NIH Clinical Center, and a version bump to v3.2.0. - Removed the previous version tag v3.1.0.SummaryDifference2%

- Check70 days agoChange DetectedUpdated the page revision from v3.0.2 to v3.1.0, indicating a new software release or document update. No changes to core content, pricing, or stock are evident.SummaryDifference0.1%

- Check85 days agoChange DetectedThe page now shows Revision: v3.0.2 (replacing v3.0.1), and the Back to Top element has been removed.SummaryDifference0.1%

Stay in the know with updates to Oral Azacitidine with Pembrolizumab in Metastatic Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Oral Azacitidine with Pembrolizumab in Metastatic Melanoma Clinical Trial page.